In a significant development in tobacco regulation and public health, the U.S. Food and Drug Administration (FDA) has renewed its modified risk orders for eight snus products by Swedish Match USA, Inc. Initially approved in 2015, these products offer a reduced-risk alternative to traditional smoking, marking an important milestone in the tobacco industry.
Products and Risk Statement
The renewal involves eight products:
- General Loose
- General Dry Mint Portion Original Mini
- General Portion Original Large
- General Classic Blend Portion White Large – 12ct
- General Mint Portion White Large
- General Nordic Mint Portion White Large – 12ct
- General Portion White Large
- General Wintergreen Portion White Large
These snus products are now authorized to carry the statement: “Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis”
The Scientific Review Process
The FDA’s decision, valid until November 7, 2032, is backed by a thorough scientific review. This process confirmed that the risk modification claims have scientific support and that consumers correctly understand the relative risks compared to smoking cigarettes. The real-world use of these products shows a significant reduction in harm and the risk of tobacco-related diseases, contributing to overall public health.
Significance of the Renewal
This renewal is a landmark as it’s the first time the FDA has extended a modified risk order since initially approving these products in 2019. After a five-year term, Swedish Match reapplied to continue sales beyond the original order’s expiration. Long-term epidemiological studies back this renewal, showcasing reduced risks of severe health issues among snus users compared to smokers, with no significant increase in youth usage.
FDA’s Caution on Marketing Claims
The FDA emphasizes that the renewed order does not allow misleading marketing. Such as suggesting FDA approval or that the products are inherently safe. The agency remains clear that no tobacco product is entirely safe and that abstaining from tobacco use is the healthiest choice.
Implications for Public Health
This decision reflects the FDA’s nuanced approach to tobacco regulation, balancing harm reduction with public health protection. As the landscape of vaping and reduced-risk products evolves, the FDA’s role will be crucial in shaping effective tobacco control strategies.
Knowledge
What is Snus Product?
Snus is a type of smokeless tobacco product that originated in Sweden. It is made from ground tobacco, salt, and water, and is typically placed under the upper lip. Unlike other forms of smokeless tobacco, snus does not require spitting, making it more discreet to use. (Actually, it looks like the Nicotine Pouches, but different ingredents)
Here are some key characteristics of snus products:
- Form: Snus is available in loose form or in small, pre-packaged pouches, similar to tea bags, which are often referred to as portions.
- Usage: Users place snus under their upper lip, where it releases nicotine and flavor. It is designed to be used without the need for spitting.
- Nicotine Delivery: Snus provides a nicotine hit similar to smoking but without the inhalation of smoke, which reduces exposure to harmful combustion by-products.
- Regulation and Health Claims: In some countries, snus is marketed as a reduced-risk alternative to smoking, as it is associated with lower risks of certain tobacco-related diseases. However, it is still a tobacco product and carries health risks.
- Legal Status: The sale of snus is banned in the European Union, except for Sweden, where it is a traditional product. It is available in the United States and other countries with varying levels of regulation.
Snus is often discussed in the context of tobacco harm reduction, as it offers a less harmful alternative to smoking for those who are unable or unwilling to quit nicotine entirely.
